

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: E11/22 - Hormones 1

Deadline: 08.02.2022

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Traceability																	
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}		
(306) 17-OH-progesterone	[nmol/L]				3							3	3	100%							3	3	100%	
Samples and groups																								
Sample A		19,3	0,59	3,1	3							3	3	100%	CRV	18,58	0,19	44%	10,4	26,8	3	3	100%	
Other					3	0						3									3			
							1x 1/36, 2x 2/66								1x 1/36, 2x 2/66									
Sample B		11,5	1,1	9,2	3							3	3	100%	CRV	11,64	0,18	44%	6,51	16,8	3	3	100%	
Other					3	0						3									3			
							1x 1/36, 2x 2/66								1x 1/36, 2x 2/66									
(303) Aldosterone	[nmol/L]				6							4	3	75%									0	
Samples and groups																								
Sample A		1,53	0,18	12	6							4	4	100%									0	
Other					6	0						4												
							1x 1/36, 1x 1/218, 1x 2/66, 3x 4/164																	
Sample B		0,507	0,08	16	6							4	3	75%									0	
Other					6	0						4												
							1x 1/36, 1x 1/218, 1x 2/66, 3x 4/164																	
(307) DHEA-S	[µmol/L]				8							8	6	75%									0	
Samples and groups																								
Sample A		8,10	1,0	13	8							8	6	75%									0	
Other					8	0						8												
							1x 4/1, 3x 4/12, 3x 4/60, 1x 4/179																	
Sample B		7,73	1,3	17	8							8	6	75%									0	
Other					8	0						8												
							1x 4/1, 3x 4/12, 3x 4/60, 1x 4/179																	
(302) 17-beta-estradiol	[pmol/L]				14							14	9	64%								14	10	71%
Samples and groups																								
Sample A		643	88	14	14							14	14	100%	CRV	651,3	8,2	30%	455	847	14	14	100%	
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		696	75	11	6	0	CVPG	669	4,5	22%	521	817									6			
(60) Roche																								
Other					8	0						8										8		
							1x 3/25, 4x 4/1, 2x 4/12, 1x 4/179								1x 3/25, 4x 4/1, 2x 4/12, 1x 4/179									
Sample B		244	57	23	14							14	9	64%	CRV	229,2	2,3	30%	160	298	14	10	71%	
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		276	52	19	6	0	CVPG	242	2,9	22%	188	296									6			
(60) Roche																								
Other					8	0						8										8		
							1x 3/25, 4x 4/1, 2x 4/12, 1x 4/179								1x 3/25, 4x 4/1, 2x 4/12, 1x 4/179									
(200) Ferritin	[µg/L]				19							18	16	89%									0	
Samples and groups																								
Sample A		84,3	26	31	19							18	16	89%									0	
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		64,2	24	37	6	0	CVPG	72,6	2,8	24%	55,1	90,1									6			
(1) Abbott																								
Other					13	0						12												
							2x 4/12, 4x 4/60, 1x 4/179, 1x 6/1, 1x 6/58, 4x 6/60																	

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: E11/22 - Hormones 1

Deadline: 08.02.2022

Test	[unit]	Comparability										Traceability											
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
Sample B		48,6	15	31	19							18	17	94%							0		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		41,9	7,7	18	6	0	CVPG	44,4	1,9	±16,8	27,6	61,2		6									
Other					13	0							12										
								2x 4/12, 4x 4/60, 1x 4/179, 1x 6/1, 1x 6/58, 4x 6/60															
(301) Cortisol	[nmol/L]				11								11	8	73%						11	8	73%
Samples and groups																							
Sample A		952	170	18	11								11	8	73% CRV	925,9	9,5	22%	722	1130	11	8	73%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		999	84	8,4	5	0	CVPG	917	7,7	16%	770	1070		5							5		
Other					6	0							6									6	
								4x 4/1, 2x 4/12								4x 4/1, 2x 4/12							
Sample B		350	44	13	11								11	9	82% CRV	355,5	4,2	22%	277	434	11	9	82%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		373	15	4,0	5	0	CVPG	353	2,7	16%	296	410		5							5		
Other					6	0							6									6	
								4x 4/1, 2x 4/12								4x 4/1, 2x 4/12							
(304) Progesterone	[nmol/L]				16								16	12	75%						16	8	50%
Samples and groups																							
Sample A		15,0	3,1	21	16								16	12	75% CRV	13,5	0,20	26%	9,99	17,1	16	12	75%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		13,4	2,3	17	6	0	CVPG	14,1	0,29	20%	11,2	17		6							6		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		17,0	1,0	6,0	5	0	CVPG	15,7	0,11	20%	12,5	18,9		5							5		
Other					5	0							5									5	
								1x 3/25, 3x 4/12, 1x 4/179								1x 3/25, 3x 4/12, 1x 4/179							
Sample B		6,11	1,1	17	16								16	13	81% CRV	5,11	0,050	26%	3,78	6,44	16	9	56%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		5,48	0,78	14	6	0	CVPG	5,62	0,14	20%	4,49	6,75		6							6		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		6,79	0,49	7,2	5	0	CVPG	6,07	0,057	20%	4,85	7,29		5							5		
Other					5	0							5									5	
								1x 3/25, 3x 4/12, 1x 4/179								1x 3/25, 3x 4/12, 1x 4/179							
(121) Total T3	[nmol/L]				2								2	1	50%								0
Samples and groups																							
Sample A		1,98	0,28	14	2								2	1	50%								0
Other					2	0							2										
								1x 4/1, 1x 4/12															
Sample B		3,31	0,16	4,8	2								2	1	50%								0
Other					2	0							2										
								1x 4/1, 1x 4/12															
(125) Free T3	[pmol/L]				19								19	18	95%								0
Samples and groups																							
Sample A		8,90	1,4	16	19								19	18	95%								0
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		7,92	1,0	13	8	0	CVPG	8,09	0,072	15%	6,87	9,31		8									
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		10,1	0,94	9,4	7	0	CVPG	10,2	0,041	15%	8,67	11,8		7									
Other					4	0							4										
								3x 4/12, 1x 4/179															
Sample B		14,9	2,9	19	19								19	19	100%								0

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: E11/22 - Hormones 1

Deadline: 08.02.2022

Test	[unit]	Comparability						Traceability															
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(123) TSH					24							24	22	92%							0		
Samples and groups	[mU/L]																						
Sample A		10,2	1,5	15	24							24	22	92%							0		
Other					4	0						4											
							1x 3/25, 2x 4/12, 1x 4/179																
Sample B		14,2	2,3	16	24							24	23	96%							0		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		11,9	0,78	6,5	9	0	CVPG	12,1	0,11	14%	10,4	13,8		9									
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		16,0	0,68	4,3	11	0	CVPG	15,9	0,055	14%	13,6	18,2		11									
Other					4	0								4									
							1x 3/25, 2x 4/12, 1x 4/179																

st_kn_np

End of report

Printed: 16.02.2022